Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 1997

View Archived Issues

Yamanouchi's overseas R&D pipeline

R&D at Mitsui Pharmaceuticals

Immunomedics granted Japanese patent for cancer diagnostic technology

Initial clinical results with LGD-1069

Combination of immunosuppression and rhIL-3 for aplastic anemia

AIDS progression and link to chemokine receptors

Sequus seeks FDA approval for new indication of Amphotec

NMDA antagonists claimed by Novartis

Akzo Nobel reveals new dopamine antagonists

Substance P antagonists described by Pfizer

Knoll claims two series of compounds for CNS disorders

Protein tyrosine kinase inhibitors from Glaxo Wellcome

Selective cGMP-PDE inhibitors claimed by Otsuka

The Rockefeller University develops OCD marker

Beth Israel evaluates bFGF for coronary artery disease

Montelukast associated wth bronchodilating effects in asthmatics

Bronchodilating effect of furosemide not secondary to prostaglandin release

First approval for Zomig; antimigraine agents in development

MP-52 enters clinic

Anticancer agent from Banyu heading for clinic

NM-702 enters phase II trials

Therics receives SBIR grant for ocular drug delivery R&D

MGI Pharma and Schein reach marketing agreement for INFeD

Astra Merck launches Lexxel in U.S.

MRC, Sankyo and Oncogene Science to develop new antiflu drugs

BBI Pharmaceuticals to fund phase I trial with soybean extract in BPH

NanoSystems and Astra Draco collaborate for respiratory disorders

Water-soluble HIV protease inhibitor from Sankyo

Advanced Viral Research and the NCI sign genetic research agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...